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Organometallic nucleoside analogues: eﬀect of
the metallocene metal atom on cancer cell line
toxicity†
Media K. Ismail, a Katie A. Armstrong,b Samantha L. Hodder,b
Sarah L. Horswell, a Louise Male, a Huy V. Nguyen, a Edward A. Wilkinson, a
Nikolas J. Hodges *b and James H. R. Tucker *a
A new chiral organometallic nucleoside analogue containing ruthenocene is reported, in which alkylthy-
mine and alkylhydroxyl groups are attached in adjacent positions on one cyclopentadienyl ring. The syn-
thetic procedures for this metallocene derivative and two control compounds are described, along with
their characterisation by cyclic voltammetry and X-ray crystallography. Their biological activities in a
human pancreatic cancer cell line (MIA-Pa-Ca-2) were signiﬁcantly lower than those of three previously
reported analogous ferrocene compounds, indicating that the choice of metallocene metal atom (Fe or
Ru) plays a pivotal role in determining the anticancer properties of these nucleoside analogues, which in
turn suggests a diﬀerent mode of action from that of a conventional nucleoside analogue.
Introduction
A topical area within the field of metal-based anticancer drug
research involves examining the eﬀect of incorporating organo-
metallic moieties into known organic drugs and related bio-
logical molecules.1,2 Ferrocene is a popular choice in this
respect as a so-called bioisosteric group2 because of its stabi-
lity and well-understood reactivity and electrochemistry. Its
incorporation into the breast cancer drug tamoxifen to form
the ferrocifen family of compounds3,4 has revealed potent
activities in diﬀerent cell lines compared to the parent com-
pound. This suggests novel modes of action related to the
redox properties of the ferrocene unit, which may help combat
drug resistance in the clinic.
Nucleoside and nucleobase analogues are an important
class of chemotherapeutic agents, with 5-fluorouracil (5-FU)5
and gemcitabine (Gem)6 being two examples of leading drugs
on the market. This presents a similar opportunity to decorate
and derivatise the components of DNA/RNA with organo-
metallic groups to give a range of new biologically active and
medicinally relevant compounds.7,8 As part of our work in this
area, we previously reported the thymidine analogue
1-(S,Rp)-Fe in which the five-membered Cp ring of ferrocene
replaced the five-membered sugar ring of the nucleoside
(Fig. 1).9 This compound demonstrated excellent anticancer
activities in a range of human cancer cell lines, with both the
hydroxyl linker and the nucleobase moiety required for
optimal cytotoxicity. A subsequent structure–activity relation-
ship (SAR) study found a correlation between the IC50 values in
cancer cells and the length of the hydroxyalkyl linker in these
so-called ferronucleosides.10 In continuation of this line of
enquiry, we next decided to consider the role played by the
metal atom in the lead compound 1-(S,Rp)-Fe, the subject of
this report. In metallocene-based drug discovery, changing the
metal from iron to ruthenium is a worthwhile endeavour,
given the stability of ruthenocene and its amenability to func-
tionalisation. Furthermore, and of particular relevance from
an SAR point of view, ruthenocenes have diﬀerent redox pro-
perties to ferrocenes, having more positive oxidation potentials
and less reversible electrochemistry.11 It follows that any diﬀer-
Fig. 1 Structures of the nucleoside thymidine (left), a generic nucleo-
side analogue (middle), and a ferronucleoside drug candidate 1-(S,Rp)-
Fe (right).
†Electronic supplementary information (ESI) available. CCDC 1953303–1953305,
1953307 and 1953308. For ESI and crystallographic data in CIF or other elec-
tronic format see DOI: 10.1039/C9DT04174E
aSchool of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT,
UK. E-mail: j.tucker@bham.ac.uk
bSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT,
UK. E-mail: n.hodges@bham.ac.uk
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ence in biological activity between the two metallocenes could
indicate the role of redox processes in the mode of action.
Indeed, work on ruthenocifen derivatives has indicated
diﬀerent anticancer activities to the ferrocifens, with their bio-
logical behaviour being more similar to the parent organic
compound tamoxifen.3,12 However, despite these findings,
other reports on the biological activities of ruthenocene com-
pounds13 or organoruthenium nucleobase derivatives8a are
relatively rare. Here we report the synthesis and anticancer
properties of 1-(S,Rp)-Ru, the direct ruthenocene analogue of
1-(S,Rp)-Fe, and two related control compounds (Fig. 2). Our
findings do indeed suggest an important role of the metal
atom in controlling the anticancer activities of these metallo-
cene-containing nucleoside analogues.
Results and discussion
Synthesis
We considered that the synthesis of 1-(S,Rp)-Ru and the two
control compounds 2-(S) and 3 would allow a direct compari-
son with the three analogous ferrocene compounds previously
reported9 and also enable similar synthetic routes to be fol-
lowed. In the case of the main target 1-(S,Rp)-Ru, this meant
building the compound up from the known acetoxy derivative
4-(R)14 (Scheme 1), which itself was prepared via a two-step
route from acetylruthenocene (see ESI†). This was then treated
with NHMe2 to give the ruthenocene version of Ugi’s amine 5-
(R),14 whose chiral purity was found to be greater than 98%, as
evidenced by chiral HPLC (see ESI†). Its X-ray structure was
determined for the first time from crystals grown from a solu-
tion of the racemate in DCM layered with hexane (see ESI†).‡
The next step was to introduce planar chirality through the
diastereoselective synthesis of 6-(R,Sp) via treatment with
n-BuLi in diethylether and then quenching with iodine in
THF. This compound was then converted to the acetoxy deriva-
tive 7-(R,Sp) by heating at 50 °C for two hours in acetic anhy-
dride. A short reaction time and a relatively low temperature
were used to avoid the elimination of the amine group to give
the alkene. The arm was then extended to three carbon atoms
by reacting with freshly prepared 1-ethoxyvinyloxy trimethyl-
silane to give the ethyl ester product 8-(S,Sp). The ester was
reduced to the corresponding alcohol 9-(S,Sp) using the mild
reducing agent DIBAL-H, before being protected with the
TBDPS group to give compound 10-(S,Sp). This compound was
then formylated in dry ether in two steps in situ by reacting
with n-BuLi in a lithium–halogen exchange reaction followed
by addition of DMF to give compound 11-(S,Sp). A Wittig reac-
tion of the aldehyde added another carbon atom to give the
alkene 12-(S,Rp), which was then converted to the primary
alcohol 13-(S,Rp) by hydroboration–oxidation with BH3·THF.
Finally, a Mitsunobu coupling reaction of the alcohol 13-(S,Rp)
with benzoyl-protected thymine gave the fully protected
product, which was treated first with TBAF to remove the silyl
group and then with ammonia in methanol to remove the
benzoyl group, giving the target compound 1-(S,Rp)-Ru. HPLC
analysis of this compound confirmed its formation in high
chiral purity (>98%, see ESI†). Crystals suitable for X-ray crys-
tallography were grown from an acetonitrile solution of the
racemate at 0 °C (Fig. 3).‡ An internal O–H⋯O H bond is
formed between the hydroxyl hydrogen atom and one carbonyl
oxygen atom in the thymine base. Intramolecular H-bonding
has previously been observed within other bioorganometallic
compounds.8d,25
The synthesis of control compounds 2-(S) and 3 also started
from compound 4-(R) and proceeded through the routes
depicted in Scheme 2. The chiral alcohol was obtained via a
linker extension reaction using 1-ethoxyvinyloxy trimethyl-
silane, followed by reduction of the ester 14-(S) with LiAlH4.
Achiral 3 was obtained in four steps, first involving elimination
of the acetoxy group to give the vinyl ruthenocene 15. Crystals
Scheme 1 Synthesis route for the target compound 1-(S,Rp)-Ru from
synthon 4-(R).
Fig. 2 Structures of the main target compound 1-(S,Rp)-Ru (middle)
and the two control compounds 2-(S) and 3 (left and right) respectively.
‡The X-ray structures of the chiral compounds were determined from crystals
grown from solutions of racemic mixtures (see the ESI† for more details).
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of this compound suitable for X-ray diﬀraction were success-
fully grown from a solution of DCM layered with hexane (see
ESI†). A hydroboration–oxidation reaction then yielded the
anti-Markovnikov product 16 containing the desired hydro-
xyethyl linker. The X-ray structure of this compound was also
obtained from crystals grown using the same conditions (see
ESI†). The route was completed using the same methodology
described earlier via a Mitsunobu coupling reaction with the
protected thymine base to give the protected product 17,
which was then deprotected with ammonia to give the target
compound 3. Crystals of the latter were grown by slow evapor-
ation from a solution of ethyl acetate layered with hexane. The
resulting X-ray structure, showing the correct bond connec-
tivity, is depicted in Fig. 4.
Electrochemistry
The electrochemistry of ruthenocene is more complicated than
that of ferrocene. The 17-electron ruthenocenium cation is
considerably more unstable and reactive than its ferrocene
counterpart with Ru(VI) products formed from both the
chemical15,16 and electrochemical11,16,17 oxidation of rutheno-
cene. The appearance of the cyclic voltammograms (CVs) of
ruthenocene and those of its derivatives is highly dependent
on the type of solvent and electrolyte.18–20 In non-coordinating
electrolyte systems and in the presence of non-coordinating
boron-containing electrolytes that do not form ion pairs, the
cation has been reported to form two diﬀerent dimers in a
temperature-dependent ratio.20,21 In coordinating solvents and
in the presence of more conventional electrolytes,18,19,22 the
behaviour is diﬀerent again. For example, a two-electron oxi-
dation has been reported in acetonitrile using [NBu4][PF6] as a
supporting electrolyte.18,23 with the cation binding to aceto-
nitrile to form [MeCN-RuCp2]
+, which then undergoes further
oxidation to give [MeCN-RuCp2]
2+ followed by a double
reduction back to ruthenocene. Given these previous findings,
it was decided to conduct CV experiments on the three target
compounds 1-(S,Rp)-Ru, 2-(S) and 3 in acetonitrile in the pres-
ence of [NBu4][PF6] and compare them with 1-(S,Rp)-Fe under
the same conditions. The experiments were performed in the
presence of decamethylferrocene (dmfc) as an internal refer-
ence, as reported previously.10
All three ruthenocene compounds showed a similar EC
(electrochemical-chemical) oxidation process at a positive
potential value, with no return wave observed under the con-
ditions used. Voltammograms of 1-(S,Rp)-Ru at diﬀerent scan
rates are displayed in Fig. 5, with those of 2-(S) and 3 pre-
sented in the ESI.† The Epa data for all three compounds are
presented in Table 1, along with the corresponding value for
the ferrocene analogue 1-(S,Rp)-Fe, which is considerably more
negative (Epa = 455 mV, E1/2 = 424 mV (ref. 10)).
This diﬀerence in value reflects the large diﬀerence in the
relative stabilities between the oxidized and reduced forms of
Fig. 3 Crystal structure of one of the two crystallographically-indepen-
dent molecules of 1-(S,Rp)-Ru with ellipsoids drawn at the 50% prob-
ability level. The structure also contains two independent molecules of
acetonitrile, which have been omitted for clarity. Intramolecular hydro-
gen bonding is shown using a dotted line.
Scheme 2 Synthesis routes for control compounds 2-(S) and 3 from
synthon 4-(R).
Fig. 4 Crystal structure of 3 with ellipsoids drawn at the 50% prob-
ability level.
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the two metallocenes, with the ferrocene derivative clearly
being thermodynamically much easier to oxidise than its
ruthenocene counterpart. The ferrocene derivative also shows
reversible electrochemistry. The more positive value of Epa for
compounds 2-(S) and 3 compared with 1-(S,Rp)-Ru can be
explained by a greater inductive eﬀect (+I) as the number of
electron donating groups on the Cp ring increases, giving
more stability to the charged ruthenocenium ion. The same
trend is observed for the analogous ferrocene control com-
pounds of 2-(S) and 3, which have Epa values of 497 mV and
540 mV respectively vs. dmfc (see ESI†).
Biological studies
The three ruthenocene compounds were next tested for cyto-
toxic activity in the pancreatic ductal adenocarcinoma cell line
MIA-Pa-Ca-2 and compared with the ferrocene counterpart 1-
(S,Rp)-Fe as well as with cisplatin. Assays were performed after
4 days incubation time using crystal violet staining. Cell viabil-
ities, expressed as a percentage of a negative control, were
plotted against concentration (µM) as shown in Fig. 6, with the
resulting IC50 values presented in Table 1. As found previously
for other cancer cell lines,9 the IC50 value for the ferrocene
derivative 1-(S,Rp)-Fe is in the low micromolar range, with a
value similar to that of cisplatin. However, the five-fold
reduction in the toxicity of the ruthenocene analogue clearly
shows that the identity of the metal ion has a significant
impact on cytotoxicity.§ It is worth noting that the control
compounds 2-(S) and 3 were even less toxic than 1-(S,Rp)-Ru,
with IC50 values of >80 µM. This agrees with our previous find-
ings on analogous and related ferrocene compounds,9,10 in
that those metallocenes that are more electron rich, for
example by having two groups attached to one cyclopentadie-
nyl ring, are more cytotoxic. Indeed the previously published
ferrocene analogues of 2-(S) and 3, which display more positive
Epa values, are less toxic than 1-(S,Rp)-Fe.
9 Overall the trend in
the biological data supports the hypothesis that there is a sig-
nificant relationship between the redox properties of the
metallocene units in this series and cancer cell line toxicity.
Conclusion
A ruthenocene-containing nucleoside analogue and two
control compounds have been synthesised and fully character-
ized by a combination of spectroscopic, X-ray crystallography
and electrochemical measurements. Their oxidation potentials
were aﬀected by the type and number of linker groups attached
to the ruthenocene unit. All three compounds showed very low
biological activities towards MIA-Pa-Ca-2 pancreatic ductal
adenoma carcinoma cells, with IC50 values for the two mono-
functionalised controls higher than that for the bis-functiona-
Fig. 5 Cyclic voltammograms of 1-(S,Rp)-Ru (1.0 mM) at various scan
rates in dry acetonitrile with an electrolyte of [NBu4][PF6] (0.1 M) and
dmfc (1.0 mM) as internal reference.
Table 1 Peak potential (Epa in mV) and IC50 values (in µM) in MIA-Pa-
Ca-2 cancer cells of ferrocene compound 1-(S,Rp)-Fe and ruthenium
compounds 1-(S,Rp)-Ru, 2(S) and 3
Compound 1-(S,Rp)-Fe 1-(S,Rp)-Ru 2-(S) 3
Epa
a 455 932 948 968
IC50
b 9.3 (7.3–12.1) 46.0 (37.7–56.6) >80 >80
aMean values at scan rates 10–100 mV s−1 versus the E1/2 of deca-
methylferrocene, at 1 mM concentration in dry acetonitrile containing
0.1 M TBAPF6, confidence limit = ±5 mV.
b The mean from three inde-
pendent biological experiments (n = 3), calculated using a variable
slope 4 parameter model in Prism V8. Values in parentheses are the
95% CI. IC50 of cisplatin = 8.3 (5.1–17.0) µM.
Fig. 6 Cytotoxicities of 1-(S,Rp)-Ru (green diamonds), 1-(S,Rp)-Fe (red
triangles) and cisplatin (blue circles) towards MIA-Pa-Ca-2 pancreatic
cancer cells determined from the crystal violet assay. Data are expressed
as a percentage of the untreated control. Cells were treated for 4 days
with each compound and the results represent the mean of three
experiments ± SD (n = 3). Data were ﬁtted to a variable slope 4 para-
meter model in Prism V8, R2 = 0.91 (cisplatin), 0.95 (1-(S,Rp)-Fe), 0.91 (1-
(S,Rp)-Ru) respectively.
§The enantiomer 1-(R,Sp)-Ru, isolated from a racemic batch of the target com-
pound (see ESI†), was found to be even less toxic, with an IC50 of >80 µM, the
highest concentration investigated. These data suggest that stereochemistry also
plays a significant role in determining the anticancer activity of these ferronu-
cleosides. This aspect is currently being investigated further and will be included
in a future report.
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lised target compound. The main finding of this study is the
five-fold diﬀerence in cytotoxicity between 1-(S,Rp)-Ru and its
ferrocene counterpart 1-(S,Rp)-Fe. Given their otherwise identi-
cal chemical structures and stereochemistries, this diﬀerence
can confidently be attributed to the change in the metal atom
from iron to ruthenium. While such a change would make
little diﬀerence to a metallocene’s size or lipophilicity, it
clearly does aﬀect its redox properties. The ferrocenes in this
series demonstrate more reversible electrochemistry than their
ruthenocene counterparts, with their oxidised forms accessible
at significantly lower potentials. These diﬀerences in electro-
chemical behaviour signify an important role of the iron atom
in determining the anticancer activity of the lead compound 1-
(S,Rp)-Fe. This in turn suggests a mode of action diﬀerent
from that of a conventional nucleoside analogue, one that
points more towards intra-cellular redox-triggered and ROS-
mediated pathways leading to cell death. This line of enquiry
is currently under investigation in our laboratory.
Experimental
Synthesis
(R)-1-α-N,N-Dimethylaminoethylruthenocene, 5-(R). 1-
α-Acetoxyethylruthenocene 4-(R) (see ESI†) (0.1 g, 3.15 mmol)
was dissolved in MeOH (3 mL). Dimethylamine (40% in H2O)
was added and the resulting solution stirred for 24 h. The reac-
tion was quenched with water, extracted with DCM, washed
with water and then brine, and dried over MgSO4. The solvent
was removed in vacuo and the crude product purified by flash
column chromatography on silica gel using an eluent of 15%
ether in hexane and 3% Et3N. The solvent was removed in
vacuo to give the title compound as a pale-yellow solid
(0.0263 g, 38%). δ H (400 MHz, CDCl3) 4.63–4.57 (m, 2H),
4.57–4.54 (m, 1H), 4.53 (s, 6H), 3.62–3.54 (m, 1H), 2.31 (s, 6H),
1.41 (d, J = 6.9 Hz, 3H). δ C (101 MHz, CDCl3) 72.4 (Cp), 71.1
(Cp), 70.2 (Cp), 70.1 (Cp), 69.5 (Cp), 59.6 (CH), 40.4 (CH3), 17.5
(α-CH3). HRMS (ES) (m/z) calcd for C14H20N102Ru 304.0639,
found 304.0636. Vmax/cm
−1 3200 (C–H), 2923 (CH2), 2851
(CH2), 2816 (CH2), 1453 (CH3), 1370 (CH3), 1100 (C–N), 806
(C–C), 720 (CH–Ar).
(R,Sp)-1-(α-N,N-Dimethylaminoethyl)-2-iodoruthenocene,
6-(R,Sp). The Ugi amine 5-(R) (0.1 g, 0.33 mmol) was dissolved
in Et2O (5 mL) at room temperature. n-BuLi (0.3 mL, 1.7 M,
2 eq.) was added and the mixture stirred overnight. The
mixture was cooled to −78 °C, and iodine (0.23 g, 0.91 mmol),
in THF (10 mL), was added over 10 min. The mixture was
stirred at −78 °C for 90 min before being warmed to room
temperature and then stirred for an additional 90 min. The reac-
tion was then quenched at 0 °C with sodium thiosulfate (10 mL,
25% w/v). After dilution with Et2O (15 mL), the layers were sep-
arated, and the aqueous layer was washed further with Et2O (3 ×
5 mL). The combined organic fractions were dried over MgSO4.
The solvent was removed in vacuo before purification via flash
column chromatography (10% Et2O and 4% TEA in hexane) to
obtain the final oily product (0.07 g, 49%). δ H (400 MHz,
CDCl3) 4.84 (dd, J = 2.2, 1.1 Hz, 1H), 4.57–4.52 (m, 2H), 4.51 (s,
5H), 3.43 (q, J = 6.8 Hz, 1H), 2.24 (s, 6H), 1.35 (d, J = 6.8 Hz,
3H). δ C (101 MHz, CDCl3) 94.9 (Cp), 77.1 (Cp), 73.7 (Cp), 71.0
(Cp), 68.7 (Cp), 57.7 (CH), 41.6 (CH3), 29.7 (ipso Cp), 18.7 (CH3).
HRMS (ES) (m/z) calcd for C14H19N
102Ru 429.9606, found
429.9604. Vmax/cm
−1 3098 (vC–H), 2963 (CH2), 2923 (CH2),
2851 (CH2), 1100 (C–H), 1453 (CH3), 1370 (CH3), 1261, 1156,
918 (CHvCH), 806 (CH Ar). [α]20D = +27(±2) (c = 0.25 in CHCl3).
(R,Sp)-1-(α-Acetoxyethyl)-2-iodoruthenocene, 7-(R,Sp).
Compound 6-(R,Sp) (1 g, 2.3 mmol) and acetic anhydride
(8.3 mL, 81 mmol) were heated at 50 °C for 2 h. Acetic anhy-
dride was removed under high vacuum (0.1 mmHg) and the
residue purified by flash column chromatography (10% Et2O
and 4%TEA in hexane) to obtain a light yellow oily product
(0.9 g, 86%). δ H (400 MHz, CDCl3) 5.67 (q, J = 6.5 Hz, 1H),
4.87 (dd, J = 2.3, 1.1 Hz, 1H), 4.68 (d, J = 2.5 Hz, 1H), 4.55 (t, J =
2.4 Hz, 1H), 4.52 (s, 5H), 2.02 (s, 3H), 1.51 (d, J = 6.5 Hz, 3H).
δ C (101 MHz, CDCl3) 170.3 (CvO), 91.9 (ipso Cp), 78.2 (Cp),
73.8 (Cp), 71.7 (Cp), 69.4 (CH), 68.9 (Cp), 39.9 (ipso Cp), 21.2
(CH3), 19.4 (CH3). HRMS (ES) (m/z) calcd for
C14H15O2Na
102Ru127I 466.9058 found 466.9054. Vmax/cm
−1
3098 (vC–H), 2979 (CH2), 2929 (CH2), 2818 (CH2), 1727
(CvO), 1449 (CH3), 1367 (CH3), 1229 (C–O), 1044, 1018, 806
(CHvCH), 752 (CH–Ar). [α]20D = +25(±2) (c = 0.25 in CHCl3).
(S,Sp)-1-[α-Methyl(2-ethylpropanoate)]-2-iodoruthenocene, 8-
(S,Sp). Compound 7-(R,Sp) (1 g, 2.25 mmol) and 1-ethoxyviny-
loxy trimethylsilane (0.9 g, 5.63 mmol) were dissolved in DCM
(20 mL). The mixture was cooled to −78 °C, and BF3·OEt2
(0.3 mL, 2.7 mmol) was then added dropwise. The mixture was
stirred for 15 min at −78 °C before being warmed to room
temperature and quenched with saturated NaHCO3 (20 mL).
The organic layer was separated, and the aqueous layer was
washed further with DCM (20 mL). The combined organic frac-
tions were dried over MgSO4. The solvent was removed in
vacuo and the residue purified via flash column chromato-
graphy (10% Et2O in hexane) to obtain a yellow oily product
(0.7 g, 66%). δ H (300 MHz, CDCl3) 4.80 (dd, J = 2.2, 1.2 Hz,
1H), 4.52 (s, 5H), 4.47–4.40 (m, 2H), 4.12 (q, J = 7.1 Hz, 2H),
2.97–2.81 (m, 1H), 2.60 (dd, J = 14.8, 4.2 Hz, 1H), 2.25 (dd, J =
14.8, 10.0 Hz, 1H), 1.29–120 (m, 6H, 2 × Me). δ C (101 MHz,
CDCl3) 172.0 (CvO), 98.6 (ipso Cp), 76.9 (Cp), 73.4 (Cp), 70.8
(Cp), 68.0 (Cp), 60.3 (CH2), 43.0 (CH2), 40.3 (ipso Cp), 30.6
(CH), 20.6 (CH3), 14.4 (CH3). HRMS (ES) (m/z) calcd for
C16H19O2Na
102Ru127I 494.9371, found 494.9373. Vmax/cm
−1
3097 (vC–H), 2973 (CH2), 2929 (CH2), 2823 (CH2), 1728
(CvO), 1459 (CH3), 1369 (CH3), 1173, 1030 (C–O), 1100, 998
(CHvCH), 805 (CH–Ar). [α]20D = −6(±2) (c = 0.25 in CHCl3).
(S,Sp)-1-[α-Methyl-(3-(hydroxyl)propyl)]-2-iodoruthenocene,
9-(S,Sp). Compound 8-(S,Sp) (0.1586 g, 0.3365 mmol) was dis-
solved in Et2O (20 mL), and the solution was cooled to 0 °C.
After stirring for 10 min, DIBAL-H (0.92 mL, 1 mmol) was
slowly added at 0 °C. The mixture was stirred for 1 h at 0 °C
before the reaction was quenched with saturated sodium pot-
assium tartrate in water (10 mL). The aqueous layer was
washed further with Et2O (15 mL). The combined organic frac-
tions were dried over Na2SO4, the solvent was removed
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in vacuo, and the residue was purified via flash column chrom-
atography (20% Et2O in hexane) to obtain a colorless solid
product (0.119 g, 82%). δ H (400 MHz, CDCl3) 4.78 (dd, J = 2.2,
1.1 Hz, 1H), 4.50 (s, 5H), 4.44 (t, J = 2.3 Hz, 1H), 4.38 (dd, J =
2.4, 0.9 Hz, 1H), 3.64–3.56 (m, 2H), 2.55–2.45 (m, 1H), 2.03 (s,
1H, br s), 1.78–1.58 (m, 2H), 1.20 (d, J = 7.0 Hz, 3H). δ C
(101 MHz, CDCl3) 100.5 (ipso Cp), 76.5 (Cp), 73.4 (Cp), 70.7
(Cp), 67.6 (Cp), 61.0 (CH2), 41.8 (CH2), 41.1 (ipso Cp), 29.8
(CH), 21.8 (CH3). HRMS (ES) (m/z) calcd for C14H17O
23Na
102Ru127I 452.9265, found 452.9269. Vmax/cm
−1 3287 br (OH),
3094 (vC–H Fc), 2955 (CH2), 2924 (CH2), 2852 (CH2), 1524,
1458 (CH2), 1374 (CH3), 1054, 997 (C–O), 805 (CvC). [α]20D =
+10(±3) (c = 0.2 in CHCl3). m.p.: 98–100 °C.
(S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-
iodoferrocene, 10-(S,Sp). Compound 9-(S,Sp) (0.2 g, 0.47 mmol)
was dissolved in DCM (15 mL) at room temperature. TEA
(0.098 mL, 0.699 mmol), tert-butyldiphenylsilyl chloride
(0.18 mL, 0.699 mmol), and DMAP (catalytic amounts) were
then added to the mixed solution. The reaction was then
stirred overnight at room temperature before quenching with
water (5 mL). The organic layer was separated, and the
aqueous layer was washed with Et2O (2 × 10 mL). The com-
bined organic fractions were dried over Na2SO4, the solvent
was removed in vacuo, and the residue was purified via flash
column chromatography (10% Et2O in hexane) to obtain a
yellow oily product (0.3 g, 96%). δ H (400 MHz, CDCl3)
7.76–7.72 (m, 4H), 7.47–7.40 (m, 6H), 4.83 (dd, J = 2.2, 1.1 Hz,
1H), 4.56 (s, 5H), 4.48 (t, J = 2.3 Hz, 1H), 4.42–4.40 (m, 1H),
3.82–3.71 (m, 2H), 2.66–2.56 (m, 1H), 2.01–1.92 (m, 1H),
1.64–1.55 (m, 1H), 1.20 (d, J = 6.9 Hz, 3H), 1.12 (s, 9H). δ C
(101 MHz, CDCl3) 135.7 (Ar), 134.1 (ipso Ar), 129.6 (Ar), 127.7
(Ar), 100.9 (ipso Cp), 76.7 (Cp), 73.3 (Cp), 70.6 (Cp), 67.7 (Cp),
62.4 (Cp), 52.3 (CH2), 41.5 (CH2), 40.8 (ipso Cp), 30.0 (CH), 27.0
(CH3), 20.9 (CH3), 19.3 (ipso t-Bu). HRMS (ES) (m/z) calcd
for C30H35O
23Na127I28Si102Ru 691.0446, found 691.0443.
Vmax/cm
−1 3070 (vCH Fc), 2956 (CH2), 2928 (CH2), 2855(CH2),
1472 (CH2), 1387 (CH3), 1307, 1187, 1108, 821 (CH–Ar TBDPS),
701 (CvC). [α]20D = +15(±2) (c = 0.25 in CHCl3).
(S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-
formylruthenocene, 11-(S,Sp). Compound 10-(S,Sp) (0.4 g,
1.001 mmol) was dissolved in extra dry Et2O (30 mL) and de-
oxygenated with argon for 15 min. The mixture was cooled to
−78 °C, and fresh n-BuLi (0.2 mL, 2.0 mmol) was added drop-
wise. After 30 min, DMF (0.08 mL, 3.0 mmol) was added, and
the mixture was stirred at −78 °C for another 30 min. The reac-
tion was then warmed to room temperature and quenched
with water (10 mL). The organic phase was separated, and the
aqueous layer was washed with Et2O (2 × 10 mL). The com-
bined organic fractions were dried over Na2SO4. The solvent
was removed in vacuo and the residue purified via flash
column chromatography (30% Et2O in hexane) to obtain a
yellow oily product (0.3 g, 88%). δ H (400 MHz, CDCl3) 9.91
(s, 1H), 7.67–7.62 (m, 4H), 7.42–7.36 (m, 6H), 5.03 (dd, J = 2.2,
1.4 Hz, 1H), 4.74–4.71 (m, 2H), 4.61 (s, 5H), 3.65 (dt, J = 6.6,
1.4 Hz, 2H), 2.95 (q, J = 6.9 Hz, 1H), 1.79–1.61 (m, 2H), 1.15 (d,
J = 6.9 Hz, 3H), 1.04 (s, 9H). δ C (101 MHz, CDCl3) 190.1
(CvO), 135.57 (Ar), 1334.0 (ipso Ar), 133.8 (ipso Ar), 129.6 (Ar),
127.6 (Ar), 101.8 (ipso Cp), 82.4 (ipso Cp), 72.7 (Cp), 72.4 (Cp),
72.4 (Cp), 70.6 (Cp), 62.0 (CH2), 42.9 (CH2), 27.5 (CH), 26.9
(CH3), 20.9 (CH3), 19.2 (ipso t-Bu). HRMS (ES) (m/z) calcd for
C31H36O2Na
102Ru28Si 593.1432, found 593.1426. Vmax/cm
−1
3096 (C–H Fc), 2958, 2931, 2856 (CH2), 1678 (CvO), 1427
(CH2), 1388 (CH3), 1109, 998 (C–O), 820, 739 (CH Ar), 703
(CvC). [α]20D = +7(±2) (c = 0.2 in CHCl3).
(S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-
vinylruthenocene, 12-(S,Rp). Triphenylmethylphosphonium
bromide (0.268 g, 0.708 mmol), potassium tert-butoxide
(0.08 g, 0.78 mmol), and dibenzo-18-crown-6-ether (catalytic
amount) were dissolved in dry THF (20 mL) under argon. The
mixture was stirred for 30 min and then 11-(S,Sp) (0.269 g,
0.472 mmol) in dry THF (5 mL) was added to the mixture. The
mixture was stirred overnight at room temperature, before
quenching with water (5 mL) and extracting with Et2O (2 ×
10 mL). The combined organic fractions were dried over
Na2SO4, the solvent was removed in vacuo, and the residue was
purified via flash column chromatography using hexane to
obtain a yellow oily product (0.215 g, 80%). δ H (400 MHz,
CDCl3) 7.66–7.62 (m, 4H), 7.42–7.34 (m, 6H), 6.48 (dd, J = 17.4,
10.8 Hz, 1H), 5.28 (dd, J = 17.4, 1.7 Hz, 1H), 4.89 (dd, J = 10.8,
1.7 Hz, 1H), 4.81 (t, J = 1.7 Hz, 1H), 4.45 (s, 5H), 4.43 (d, J =
3.9 Hz, 1H), 3.65–3.60 (m, 2H), 2.70–2.63 (m, 1H), 1.79–1.70
(m, 1H), 1.58–1.54 (m, 1H), 1.12 (d, J = 6.9 Hz, 3H), 1.04 (s, 9H,
Me). δ C (101 MHz, CDCl3) 135.6 (Ar), 134.1 (ipso Ar), 132.7
(CH), 129.5 (Ar), 127.6 (Ar), 111.2 (CH2), 98.7 (ipso Cp), 86.7
(ipso Cp), 71.4 (Cp), 70.7 (Cp), 68.9 (Cp), 68.5 (Cp), 66.9 (Cp),
62.2 (CH2), 42.5 (CH2), 27.5 (CH), 26.9 (CH3), 20.6 (CH3), 19.2
(ipso t-Bu). HRMS (ES) (m/z) calcd for C32H39O
102RuSi
569.1829, found 569.1814. Vmax/cm
−1 3070 (C–H Fc), 2958
(CH2) 2928 (CH2), 2856 (CH2), 1627 (CvC Ar), 1471 (CH2),
1388 (CH3), 1108, 1086 (C–O), 821, 806 (C–H Ar), 700 (vinyl/
CvC). [α]20D = +52(±3) (c = 0.2 in CHCl3).
(S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-[2-
(hydroxyl)ethyl] ruthenocene, 13-(S,Rp). Compound 12-(S,Rp)
(0.215 g, 0.379 mmol) was dissolved in dry THF (15 mL).
BH3·THF (1 M, 1.1 mL, 1.084 mmol) was then added dropwise
at room temperature and the mixture was stirred for 2 h. EtOH
(1.4 mL), NaOH solution (3 M, 1.4 mL, 3.79 mol), and H2O2
(30 wt% in water, 0.73 mL, 8.338 mmol) were then added suc-
cessively, and the mixture was stirred for 1 h at room tempera-
ture. The reaction mixture was added to DCM (20 mL), washed
with brine (10 mL), and then dried over Na2SO4. The solvent
was removed in vacuo and the residue purified via flash
column chromatography (10% EtOAc in hexane) to obtain a
yellow oily product (0.17 g, 77%). δ H (400 MHz, CDCl3)
7.68–7.62 (m, 4H), 7.43–7.34 (m, 6H), 4.52 (s, 5H), 4.51–4.50
(m, J = 1.0 Hz, 1H), 4.41 (dd, J = 2.2, 1.1 Hz, 1H), 4.37 (t, J = 2.3
Hz, 1H), 3.71–3.56 (m, 4H), 2.53–2.31 (m, 3H), 1.76–1.70 (m, 1H),
1.56–1.47 (m, 1H), 1.07 (d, J = 6.9 Hz, 3H), 1.05 (s, 9H). δ C
(101 MHz, CDCl3) 135.6 (Cp), 134.0 (ipso Ar), 129.6 (CH Ar), 127.7
(Ar), 99.8 (ipso Cp), 87.4 (ipso Cp), 71.2 (Cp), 70.4 (Cp), 68.0 (Cp),
62.9 (CH2), 62.2 (CH2), 42.0 (CH2), 28.7 (CH2), 27.2 (CH), 26.9
(CH3) 21.4 (CH3), 19.2 (ipso t-Bu). HRMS (ES) (m/z) calcd for
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C32H40O2NaSi
102Ru 609.1759, found 609.1739. Vmax/cm
−1 3420 br
(OH), 3071 (vC–H Fc), 2955 (CH2), 2927 (CH2), 1589, 1470 (CH3),
1427 (CH2), 1388 (CH3), 1361, 1109, 997 (C–O), 822, 738 (C–H Ar),
702 (vC–H). [α]20D = +45(±3) (c = 0.25 in CHCl3).
(S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-[(thyminyl)ethyl]-
ruthenocene, 1-(S,Rp)-Ru. Triphenylphosphine (160 mg,
0.6 mmol), N3-benzoylthymine (110 mg, 0.5 mmol), and 13-(S,
Rp) (92 mg, 0.2 mmol) were dissolved in THF (10 mL) in a
100 mL Schlenk tube, and the mixture was stirred for 10 min
at room temperature. The tube was then covered with foil, and
DIAD (0.12 mL, 0.6 mmol) was added. The mixture was then
heated to 65 °C for 2 h. The solvent was evaporated, and the
resulting residue was dissolved in EtOAc (20 mL), washed with
brine (10 mL) followed by water (5 mL), and dried over Na2SO4.
The solvent was removed in vacuo and the residue purified via
flash column chromatography (15% Et2O in hexane) to give
the fully protected product. Deprotection was achieved by stir-
ring the compound in TBAF (5 mL) for 2 h. The solvent was
removed, and the residue was then redissolved in ammonia in
methanol (7 N, 2 mL) and stirred at room temperature for
30 min. The solvent was evaporated, and the crude product
was purified via flash column chromatography (5% MeOH in
DCM) to obtain the product as a white solid (105 mg, 74%).
δ H (400 MHz, CDCl3) 9.33 (s br, 1H), 7.04 (s, 1H), 4.50 (s, 5H),
4.45 (dd, J = 2.2, 1.2 Hz, 2H), 4.41 (t, J = 2.3 Hz, 1H), 3.86–3.77
(m, 1H), 3.74–3.62 (m, 3H), 2.68–2.54 (m, 3H), 2.40 (s br, 1H),
1.92 (s, 3H), 1.78–1.73 (m, 1H), 1.65–1.57 (m, 1H), 1.18 (d, J =
6.9 Hz, 3H). δ C (101 MHz, CDCl3) 164.2 (CvO), 151.1 (CvO),
140.4 (CH thymine), 111.0 (ipso thymine), 95.3 (ipso Cp), 80.7
(ipso Cp), 69.3 (Cp), 67.6 (Cp), 65.9 (Cp), 65.3 (Cp), 60.2 (CH2),
49.8 (CH2), 43.2 (CH2), 27.9 (CH2), 27.1 (CH), 19.2 (CH3
thymine), 12.3 (CH3). HRMS (ES) (m/z) calcd for
C21H26N2O3NaFe 433.1191, found 433.1182. Vmax/cm
−1 3462 br
(OH), 3097 (vC–H Fc), 2954 (CH2), 2926 (CH2), 1669 (CvO),
1468, 1425 (CH3), 1425 (CH2), 1383 (CH3), 1353 (C–N) 1100,
1036, 997 (C–O), 805, 759 (C–H Ar), 690, 669 (vC–H). [α]20D =
+42(±3) (c = 0.1 in CH3CN).
(S)-1-[α-Methyl(2-ethylpropanoate)]ruthenocene, 14-(S).
1-Methoxyethylruthenocene 4-(R) (0.9 g, 2.84 mmol, 1.0 eq.)
was dissolved in dry DCM and stirred at −78 °C for 5 min
under an atmosphere of argon. 1-Ethoxyvinyloxy trimethyl-
silane (1 mL, 6.2 mmol, 2.2 eq.) was added and the mixture
stirred for 5 min. BF3·Et2O (0.43 mL, 3.4 mmol, 1.2 eq.) was
added dropwise and the solution stirred for 20 minutes at
−78 °C. The solution was warmed to room temperature over
30 min and then stirred for another 30 min. The reaction was
quenched with sat. NaHCO3, extracted with DCM and dried
over MgSO4. The solvent was removed in vacuo and the crude
product purified by flash column chromatography on silica gel
using an eluent system of 15% Et2O in hexane. The solvent
was removed in vacuo to give the title compound as a yellow oil
(0.61 g, 63%). δ H (400 MHz, CDCl3) 4.52 (s, 5H), 4.48 (t, J = 1.7
Hz, 2H), 4.45–4.42 (m, 2H), 4.13 (q, J = 7.3 Hz, 2H), 2.86–2.75
(m, 1H), 2.52 (dd, J = 14.9, 5.4 Hz, 1H), 2.27 (dd, J = 14.9, 9.2
Hz, 1H), 1.25 (t, J = 7.2 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H). δ C
(101 MHz, CDCl3) 172.76 (CvO), 98.3 (ipso Cp), 70.5 (Cp), 70.1
(Cp), 69.5 (Cp), 68.9 (Cp), 60.3 (CH2), 43.7 (CH2), 29.6 (CH),
21.5 (CH3), 14.3 (CH3). HRMS (ES) (m/z) calcd for
C16H19O2
102Ru 346.0507, found 346.0508. Vmax/cm
−1 3095 (C–
H), 2964, 2929 (CH2), 1731 (CvO), 1369 (CH3), 1030 (C–O), 817
(vC–H). [α]20D = +10.5(±2) (c = 0.1 in CHCl3).
(S)-1-[α-Methyl-(3-(hydroxy)propyl)]ruthenocene, 2-(S).
Compound 14-(S) (0.48 g, 1.39 mmol, 1 eq.) was dissolved in
dry THF and stirred at 0 °C for 5 min under an atmosphere of
argon. LiAlH4 (0.11 g, 2.78 mmol, 2 eq.) was added slowly, and
the solution stirred for two hours at RT. The reaction was
quenched with a saturated solution of sodium potassium-tar-
trate (10 mL), extracted with diethylether and dried over
MgSO4. The solvent was removed in vacuo and the crude
product purified by flash column chromatography on silica gel
using an eluent system of 15% Et2O in hexane. The solvent
was removed in vacuo to give the title compound as a yellow
oily product (0.35 g, 83%). δ H (400 MHz, CDCl3) 4.53 (s, 5H),
4.51–4.48 (m, 2H), 4.47–4.42 (m, 2H), 3.73–3.60 (m, 2H),
2.47–2.36 (m, 1H), 1.77–1.67 (m, 1H), 1.66–1.58 (m, 1H), 1.55
(s br, 1H), 1.12 (d, J = 6.9 Hz, 3H). δ C (101 MHz, CDCl3) 99.4
(ipso Cp), 70.5 (Cp), 70.1 (Cp), 69.4 (Cp), 69.2 (Cp), 68.6 (Cp),
61.3 (CH2), 41.4 (CH2), 29.3 (CH), 21.8 (CH3). HRMS (ES) (m/z)
calcd for C14H18O
102Ru 304.0401 found 304.0389. Vmax/cm
−1
3328, 3092 (C–H), 2926 (CH2), 1372 (CH3), 1050, 1029 (C–O),
999, 815 (vC–H). [α]20D = +13(±2) (c = 0.1 in CHCl3).
1-Vinylruthenocene, 15. 1-Methoxyethylruthenocene 4-(R)
(0.23 g, 0.95 mmol, 1.0 eq.) and LiBr (0.8 g, 9.5 mmol, 10 eq.)
were dissolved in DMF (7 mL) under an atmosphere of argon.
The reaction was heated gradually to 80 °C and stirred for
30 min. The reaction was quenched with water (20 mL),
extracted with DCM and dried over MgSO4. The solvent was
removed in vacuo and the crude product purified by flash
column chromatography on neutralized silica gel using 15%
Et2O and 3% TEA in hexane. The solvent was removed in vacuo
to give the title compound as a yellow solid (0.15 g, 61%). δ H
(300 MHz, CDCl3) 6.33 (dd, J = 17.5, 10.7 Hz, 1H), 5.28 (dd, J =
17.5, 1.5 Hz, 1H), 4.89 (dd, J = 10.7, 1.5 Hz, 1H), 4.77 (t, J = 1.7
Hz, 1H), 4.56 (s, 5H), 4.51 (s, 3H). δ C (101 MHz, CDCl3) 133.8
(CH vinyl), 111.0 (CH2 vinyl), 87.6 (ipso Cp), 71.1 (Cp), 70.5
(Cp), 70.1 (Cp), 69.0 (Cp). HRMS (m/z) calcd for C12H12
102Ru
257.9982, found 257.9979. Vmax/cm
−1 3094 (C–H), 2958, 2915,
2848 (CH2), 1734, 1461, 1367 (CvC), 805, 753 (vC–H).
1-(β-Hydroxyethyl) ruthenocene, 16. Compound 15 (0.23 g,
0.84 mmol, 1.0 eq.) was dissolved in dry THF (10 mL) under an
atmosphere of argon. BH3·THF (1 M in THF) (1.3 mL,
1.25 mmol, 1.5 eq.) was added dropwise and the resulting
solution was stirred for 2 h. EtOH (1.3 mL) was added drop-
wise followed by NaOH solution (3 M in H2O) (1.3 mL) and
H2O2 (30 wt% in water, 1.3 mL) and the solution stirred for
2 h. The reaction was quenched with H2O, extracted with DCM
and then dried over MgSO4. The solvent was removed in vacuo
and the crude product purified by flash column chromato-
graphy on silica gel using an eluent of 20% EtOAc in hexane.
The solvent was removed in vacuo to give the title compound
as a yellow oil (0.15 g, 66%). δ H (400 MHz, CDCl3) 4.57–4.55
(m, 6H), 4.49 (t, J = 1.6 Hz,2H), 3.67 (t, J = 6.0 Hz, 2H), 2.66 (s
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br, 1H), 2.44 (t, J = 6.0 Hz, 3H). δ C (101 MHz, CDCl3) 88.5
(ipso-Cp), 71.2 (Cp), 70.8 (Cp), 69.8 (Cp), 62.9 (CH2), 30.8
(CH2). HRMS (m/z) calcd for C12H14ONa
102Ru 298.9986, found
298.9988. Vmax/cm
−1 3328, 3089 (vC–H Fc), 2926, 2874 (CH2),
1037, 999 (C–O), 813 (C–H).
2-[(Thyminyl)ethyl]-ruthenocene, 3. Triphenylphosphine
(0.149 g, 0.567 mmol), N3-benzoylthymine (0.11 g,
0.49 mmol), and 16 (53 mg, 0.189 mmol) were dissolved in
THF (10 mL) and the mixture was stirred for 10 min at room
temperature. The flask was then covered with foil, and DIAD
(0.11 mL, 0.57 mmol) was added. The mixture was heated to
65 °C for 2 h. The solvent was evaporated and the residue
redissolved in EtOAc (15 mL), washed with brine (10 mL) and
water (5 mL), and dried over Na2SO4. The solvent was removed
in vacuo to obtain the protected product. Deprotection of the
benzoyl group was achieved by treating the crude with
ammonia solution (7 N in methanol, 5 mL) for 1 h. The
solvent was then removed in vacuo and the residue purified via
flash column chromatography (30% EtOAc in hexane) to give
the product (43 mg, 59%). m.p.: 238–239 °C. δ H (400 MHz,
CDCl3) 8.75 (s br, 1H), 6.84 (s, 1H), 4.54 (s, 5H), 4.47 (s, 4H),
3.76 (t, J = 7.4 Hz, 2H), 2.55 (t, J = 7.4 Hz, 2H), 1.88 (d, J = 1.1
Hz, 3H). δ C (101 MHz, CDCl3) 164.2 (CvO), 150.6 (CvO),
140.9 (CH–thymine), 110.2 (ipso thymine), 87.2 (ipso-Cp), 70.9
(Cp), 70.7 (Cp), 70.0 (Cp), 50.8 (CH2), 28.8 (CH2), 12.2 (CH3).
HRMS (m/z) calcd for C17H18N2O2
102Ru23Na 407.0309, found
407.0311. Vmax/cm
−1 3210 (NH), 3089 (vC–H Fc), 2954 (CH2),
2921 (CH2), 2850 (CH2), 1685, 1672 (CvO), 1462, 1385 (CH3),
1353 (C–N), 803, 759 (CvC).
Electrochemistry
Cyclic voltammetry measurements were performed using
1.0 mM solutions in dry and de-oxygenated MeCN containing
tetrabutylammonium hexafluorophosphate (TBAPF6) electrolyte
at a concentration of 0.1 M and 1.0 mM dfmc as internal refer-
ence. Data were measured with a BioAnalytical Systems Inc.
(West Lafayette, IN) EC Epsilon potentiostat and with a C3 cell
stand with a three-electrode unit. The cyclic voltammograms
were recorded under argon at room temperature using a three-
electrode cell. The electrodes were obtained from IJ Cambria
(Llanelli, Wales). A platinum wire was used as a counter elec-
trode (CE), a glassy carbon electrode with 3 mm diameter was
used as a working electrode (WE) and an Ag|AgCl|3 M KCl
electrode was used as a reference electrode (RE) and connected
to the cell via a frit. Cleaning of all glassware was achieved
by soaking overnight in 1 : 1 ammonia (35%) and hydrogen
peroxide (30%), followed by multiple rinsing with ultrapure
water (from a Millipore tandem Elix-A10 system, resistivity
>18 MΩ cm, TOC < 5 ppb). The glassware was then left overnight
in ultrapure water, then rinsed again and dried in an oven prior
to use. The electrodes were cleaned as follows before their use:
the RE was cleaned with dry acetonitrile and the CE was flame
annealed. The WE was cleaned by polishing with aqueous slur-
ries of successively finer grades of alumina (1.0 μm, 0.3 μm and
0.05 μm) and then rinsed with ultrapure water and MeCN, dried
with a flow of argon, and then kept in an analyte solution.
X-ray crystallography
Crystal structure determination of 1-(S,Rp)-Ru.
C23H29N3O3Ru (M = 496.56 g mol
−1): triclinic, space group P1ˉ
(no. 2), a = 12.1133(5) Å, b = 12.9420(7) Å, c = 15.0302(8) Å, α =
70.115(5)°, β = 84.171(4)°, γ = 84.068(4)°, V = 2198.4(2) Å3, Z =
4, T = 100.01(10) K, μ(CuKα) = 6.008 mm−1, Dcalc = 1.500 g
cm−3, 15 146 reflections measured (7.284° ≤ 2Θ ≤ 136.502°),
8029 unique reflections (Rint = 0.0314, Rsigma = 0.0440) which
were used in all calculations. The final R1 was 0.0498 (I > 2σ(I))
and wR2 was 0.1326 (all data). The structure contains two crystal-
lographically-independent molecules and also two independent
molecules of acetonitrile. The hydrogen atoms bonded to N(3),
O(23), N(103) and O(123) were located in the electron density
map and their positions refined, with N(3)–H(3) subjected to a
bond distance restraint. All remaining hydrogen atoms were fixed
as riding models and the isotropic thermal parameters (Uiso) of
all hydrogen atoms were based on the Ueq of the parent atom.
Crystal structure determination of 3. C17H18N2O2Ru (M =
383.40 g mol−1): triclinic, space group P1ˉ (no. 2), a = 5.9641(4)
Å, b = 8.3166(7) Å, c = 15.9058(16) Å, α = 98.820(7)°, β = 95.605
(6)°, γ = 104.953(6)°, V = 745.39(11) Å3, Z = 2, T = 100.01(10) K,
μ(CuKα) = 8.584 mm−1, Dcalc = 1.708 g cm−3, 4176 reflections
measured (11.206° ≤ 2Θ ≤ 136.494°), 4176 unique reflections
(Rsigma = 0.0400) which were used in all calculations. The final
R1 was 0.0369 (I > 2σ(I)) and wR2 was 0.0967 (all data). The
crystal was a non-merohedral twin with the two domains
related by 180° about the reciprocal direction [0 0 1] with the
refined percentage ratio 59.4(1) : 40.6(1). The hydrogen atom
bonded to N(3) was located in the electron density map and its
position refined. All remaining hydrogen atoms were fixed as
riding models and the isotropic thermal parameters (Uiso) of
all hydrogen atoms were based on the Ueq of the parent atom.
Crystal structure determination of 5-(R). C14H19NRu (M =
302.37 g mol−1): monoclinic, space group P21/c (no. 14), a =
7.6382(3) Å, b = 20.2298(9) Å, c = 8.0749(3) Å, β = 99.314(4)°,
V = 1231.27(9) Å3, Z = 4, T = 100.01(10) K, μ(CuKα) =
10.053 mm−1, Dcalc = 1.631 g cm
−3, 4460 reflections measured
(8.742° ≤ 2Θ ≤ 138.252°), 2291 unique reflections (Rint = 0.0261,
Rsigma = 0.0371) which were used in all calculations. The final R1
was 0.0280 (I > 2σ(I)) and wR2 was 0.0670 (all data).
Crystal structure determination of 15. C12H12Ru (M =
257.29 g mol−1): monoclinic, space group P21/c (no. 14), a =
11.9888(12) Å, b = 5.6864(5) Å, c = 14.2237(16) Å, β = 100.876
(9)°, V = 952.26(16) Å3, Z = 4, T = 100(2) K, μ(MoKα) =
1.590 mm−1, Dcalc = 1.795 g cm
−3, 3039 reflections measured
(5.834° ≤ 2Θ ≤ 55.172°), 3039 unique reflections (Rsigma =
0.0354) which were used in all calculations. The final R1 was
0.0732 (I > 2σ(I)) and wR2 was 0.2153 (all data). The crystal was
a non-merohedral twin with the two domains related by 180°
about the reciprocal direction [1 0 0] with the refined percen-
tage ratio 54.2(3) : 45.8(3).
Crystal structure determination of 16. C12H14ORu (M =
275.30 g mol−1): trigonal, space group P3ˉ (no. 147), a = 30.3009
(5) Å, c = 5.97018(11) Å, V = 4747.12(18) Å3, Z = 18, T = 100.00
(10) K, μ(CuKα) = 11.714 mm−1, Dcalc = 1.733 g cm−3, 21 374
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reflections measured (5.834° ≤ 2Θ ≤ 144.214°), 6213 unique
reflections (Rint = 0.0387, Rsigma = 0.0342) which were used in all
calculations. The final R1 was 0.0445 (I > 2σ(I)) and wR2 was
0.0953 (all data). The structure contains three crystallographi-
cally-independent molecules. The hydrogen atoms bonded to
O(1), O(101) and O(201) were located in the electron density map
and their positions and thermal parameters were freely refined.
CCDC 1953303–1953305, 1953307 and 1953308 contain the
supplementary crystallographic data for this paper.†
Biological studies
MIAPaCa2 (85062806) pancreatic ductal adenoma cancer cells
were purchased from the European Collection of
Authenticated Cell Cultures. Cell culture media and sup-
plements were purchased from Gibco (Thermo Scientific). All
plasticware was purchased from Greiner Bio-One. Cells were
maintained at 37 °C in a 5% CO2 humidified incubator and
grown in T75 tissue culture flasks in DMEM supplemented with
10% (v/v) foetal bovine serum, 100 U mL−1 penicillin, 100 µg
mL−1 streptomycin, and 2 mM L-glutamine. Cells were sub-cul-
tured twice weekly before confluency using a standard trypsin-
EDTA protocol. Cell cultures were confirmed to be free from
Mycoplasma sp. contamination using the EZ-PCR mycoplasma
detection kit according to the manufacturer’s instructions.
Crystal violet assay. Cells were sub-cultured in 96-well plates
at a density of 6250 cells per well in 100 µL of complete DMEM
and left overnight to allow the cells to attach. The next day
culture media were removed and replaced with fresh media
containing test compounds (0–80 µM) dissolved in DMEM
with a final concentration of 0.5% v/v DMSO prepared from
50 mM stock solutions, except for cisplatin which was prepared
as a 2 mM stock solution in phosphate buﬀered saline (PBS).
All cultures were incubated for 72 h prior to commencement of
the crystal violet assay as described below. The old media were
removed, the cells were washed with 100 μL of PBS, and then
100 μL of 4% v/v paraformaldehyde was added. After 15 min
this was removed and 100 μL of crystal violet solution (0.5% w/v
in 10% v/v ethanol) was added and the plates were incubated
for 20 min. Next the crystal violet solution was removed, and
the plates were washed with PBS (4 × 100 μL) before being
allowed to air dry for 20 min at room temperature. Finally, the
samples were solubilized using 10% v/v acetic acid before
measuring the absorbance at 590 nm using a well-plate reader.
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